filmov
tv
Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug
Показать описание
Biogen made a surprise reversal on its Alzheimer's treatment drug with plans to now seek regulatory approval. Biogen CEO Michel Vounatsos joins CNBC's "Squawk Box" team to discuss the change.
0:07:54
Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug
0:01:18
Biogen CEO Michel Vounatsos to step down following troubled Alzheimer's drug launch
0:05:41
Biogen CEO Michel Vounatsos: We Need To Be The 'Tesla' Of Drug Pricing Model | CNBC
0:02:20
Biogen CEO, Michel Vounatsos on going beyond carbon neutral to achieve zero emissions by 2040
0:01:12
Biogen CEO, Michel Vounatsos on how the Pharma Industry must reduce its impact on the planet
0:05:17
Biogen CEO: Alzheimer's drug shows positive results
0:20:40
BIOGEN CEO: Keeping Priority on the Biggest Diseases
0:03:49
Biogen CEO on FDA approval for its Alzheimer's drug
0:03:55
Biogen CEO's surprising step-down
0:06:51
Biogen Has Breakthrough Alzheimer's Drug
0:01:32
Biogen CEO to step down after Alzheimer's drug snags
0:01:49
Biogen Confident, Will Compete with Lilly on Alzheimer's Drugs - CEO
0:01:03
Focused on the Patient
0:01:53
FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades
0:02:04
FDA approves Biogen Alzheimer's treatment
0:02:41
Analyst on what Biogen's Alzheimer's drug means for the company
0:02:56
Biogen shares spike after FDA approves Alzheimer's drug
0:01:16
Biogen's CEO and Work Experience - Q1 2019
0:02:58
Evidence to approve Biogen's Alzheimer's drug was not 'sufficient': Penn's ...
0:01:48
Biogen reopens following FDA approval of company's Alzheimer drug
0:03:55
Biogen's CEO Is 'Very Excited' About Potential Alzheimer's Drug
0:00:48
Plea to Biogen CEO from Lisa Stockman Mauriello's Sister-in-Law
0:04:32
FDA's historic approval of Biogen's Alzheimer's drug
0:03:42
An Interview with Marina Vasiliou Vice President, Managing Director of Biogen
Комментарии